Entrada Therapeutics

Entrada Therapeutics

TRDA· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -40.5% in FY2025

Dipal Doshi is the CEO of Entrada Therapeutics and was paid $3.8M in FY2025 (Dec), down 1%.

Pay$100 in the stock at the end of FY21 → $60
CEO pay is from each Entrada Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Dipal DoshiFY2025
  2. 2Nathan J. DowdenFY2024
  3. 3Natarajan Sethuraman Ph. D.FY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Entrada Therapeutics paid its 2 named executives $6.1M in total in FY2025 (Dec). CEO Dipal Doshi was paid $3.8M of that.

Name
Dipal DoshiChief Executive Officer
Natarajan Sethuraman Ph. D.President of Research and Development
Nathan J. DowdenPresident and Chief Operating OfficerNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Entrada Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Activity

Filings6

See all
Proxy statementDEF 14AApr 24, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 25, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AApr 29, 2024FY2023
Annual report10-KMar 13, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data